TerminatedNot Applicable

Feasibility of Digital Thermal Monitoring to Assess Endothelium-Dependent Vasodilation in Patients Undergoing Hematopoietic Cell Transplantation (HCT)

Stopped: \<75% participation

United States27 participantsStarted 2021-06-30

Plain-language summary

The Vendys II, an FDA-approved device, uses finger digital thermal monitoring (DTM) after a period of blood flow restriction to evaluate vascular health. This study will evaluate the feasibility of using this device to measure the Vascular Reactivity Index (VRI) in children and adolescents/young adults (AYA) undergoing hematopoietic cell transplantation (HCT).

Who can participate

Age range6 Years – 26 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Any preparative regimen.

Exclusion criteria

✕. Any subject with an injury or deformation to the index finger which prevents proper fit of the device.

What they're measuring

The use of VENDYS-II in children and AYA as a measure of vascular endothelial function.

Timeframe: through study completion, an average of 1 year

Trial details

NCT IDNCT05029752

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-08-29

View on ClinicalTrials.gov More Vascular trials